Editorial
Middle East Journal of Cancer; April 2024; 15(2): 87-88

Molecular Characterization and Metastatic Gene Signatures Based on Targeted Cancer Treatment Modalities

Sami El Khatib♦, PhD

Department of Biomedical Sciences, School of Arts and Sciences, Lebanese International University, Khiyara-West Bekaa, Lebanon

Please cite this article as: El Khatib S. Molecular characterization and metastatic gene signatures based on targeted cancer treatment modalities. Middle East J Cancer. 2024;15(2):87-8. doi: 10.30476/mejc.2023.97702.1875.

Despite being the hallmark of the illness and being responsible for up to 90% of cancer-related deaths, metastasis is the part of cancer pathophysiology that is least understood.[1] Cancer cells can infiltrate, settle, and colonize through their interaction with the tumor microenvironment (TME), which facilitates their passage through stromal barriers. The initial tumor persists and extravasates into the parenchyma of distant tissues throughout the vascular walls after intravasation into the surrounding tissues via the lymphatic and blood system's microvasculature. This invasiveness encourages the formation of micro-metastatic colonies by cancer cells in the parenchyma, which eventually grow to produce overt, clinically apparent metastatic lesions (colonization).[2] Additionally, several clones with inherent cellular plasticity may have variable degrees of metastatic potential within a population of cancer cells. The TME, which consists of immune cells, fibroblasts, endothelial cells, pericytes, bulk tumors, and tumor stromal cells, can affect cancer development by generating cytokines that encourage or inhibit cancer growth and invasion.[3] Stephen Paget's "seed and soil theory" for cancer spread postulates that the TME may operate as a determining factor, analogous to Darwin's "natural selection," to distinguish clones that can spread from the central location to distant regions.[4] Scientists must thoroughly understand the fundamental concepts underlying the metastatic process to find open therapeutic windows for efficient medicines. Such efforts will help scientists understand the metastatic process better and develop practical and pioneering approaches to hinder the progression of cancer metastasis in the future.[5]

Alternatively, the complexity and consistency of the complex clinical and genetic data have raised serious concerns. How should essential genes be found to enhance antimetastatic therapeutic options and stop or delay tumor metastatic spread? How can metastases be detected during treatment with high specificity and sensitivity? Finding out these genes' molecular functional properties and modes of action is the first step in developing a precise therapeutic benefit for cancer patients. Another crucial issue is how the

♦Corresponding Author:
Sami El Khatib, PhD
Department of Biomedical Sciences, Lebanese International University, Khiyara-West Bekaa, Lebanon
Email: sami.khatib@liu.edu.lb

Received: January 08, 2023; Accepted: October 22, 2023

current treatment affects every gene and pathway linked to metastasis. Despite essential developments and an advanced understanding of the biology of tumor metastasis, the treatment plan for many contemporary patients is insufficient because of lethal metastases. Importantly, improved tumor models and modern technologies have made it possible to establish unique gene signatures that predict the spread of metastatic disease to particular body sites. The goal of future treatment studies based on genetic markers should be to quickly identify cancer patients who are most prone to experience distant metastases. By identifying those patients who will benefit from therapeutic targeting of genes and pathways related to metastatic disease while avoiding unnecessary treatment, it will be possible to develop more cost-effective metastatic therapies that will reduce morbidity and mortality caused by this systemic disease.

Previous studies on metastasis have demonstrated that cancer stem cells (CSCs) are crucial for tumor development, immune evasion, co-selection of metastatic microenvironments, and recurrence in distant organs.[6] To improve metastasis prevention and therapy, it is crucial to have a mechanistic understanding of how molecular factors influence CSC features. Even though the current research indicates that CSC plays a substantial role in metastatic colonization, effective therapeutic targeting of these cells may still be necessary to get a better understanding of metastasis and design more effective treatments.[7]

A substantial research focus suggests that extracellular vesicles produced by CSC may contribute to metastasis, stemness, and changes in the tumor immunological environment.[8] To target CSCs with precision medicine and better prognosis and hinder cancer spread, it is essential to comprehend the cell communication pathways in the TME. The metabolic regulatory interaction between CSC and TME in the maintenance of metastasis in distant organs is another fascinating element of metastasis research that should attract further interest. There is still much to learn about how metabolic plasticity and TME affect CSC, which calls for more study that might result in the discovery of novel therapeutic targets.[9,10]

References

1. Gupta GP, Massagué J. Cancer metastasis: building a framework. *Cell.* 2006;127(4):679-95. doi: 10.1016/j.cell.2006.11.001.
2. Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour heterogeneity and metastasis at single-cell resolution. *Nat Cell Biol*. 2018;20(12):1349-60. doi: 10.1038/s41556-018-0236-7.
3. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med.* 2013;19(11):1423-37. doi: 10.1038/nm.3394.
4. Paget S. The distribution of secondary growths in cancer of the breast. *Cancer Metastasis Rev*. 1989; 8(2):98-101.
5. Albini A, Mirisola V, Pfeffer U. Metastasis signatures: genes regulating tumor-microenvironment interactions predict metastatic behavior. *Cancer Metastasis Rev.* 2008;27(1):75-83. doi: 10.1007/s10555-007-9111-x.
6. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. *Cell Res.* 2007;17(1):3-14. doi: 10.1038/sj.cr.7310118.
7. Wu M, Zhang X, Zhang W, Chiou YS, Qian W, Liu X, et al. Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. *Nat Commun.* 2022;13(1):1371. doi: 10.1038/s41467-022-29018-9.
8. Wang Z, Zöller M. Exosomes, metastases, and the miracle of cancer stem cell markers. *Cancer Metastasis Rev.* 2019;38(1-2):259-95. doi: 10.1007/s10555-019-09793-6.
9. Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. *Br J Cancer.* 2016; 114(12):1305-12. doi: 10.1038/bjc.2016.152.
10. Tyagi A, Wu SY, Sharma S, Wu K, Zhao D, Deshpande R, et al. Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis. *Oncogene.* 2022;41(22):3079-92. doi: 10.1038/s41388-022-02322-w.